Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549697 | 0.90 | MAP3K11 (0.38) | KDM1AMAP3K11DYRK2DRD2DRD3 | |
| SCHEMBL2551140 | 0.90 | TTK (0.38) | — | |
| SCHEMBL2554752 | 0.90 | MAP3K11 (0.34) | KDM1AMAP3K11DYRK2DRD2DRD3 | |
| SCHEMBL2552056 | 0.90 | RPS6KA5 (0.35) | KDM1AMAP3K11DYRK2DRD2DRD3 | |
| SCHEMBL2546139 | 0.89 | RPS6KA5 (0.34) | KDM1AMAP3K11DYRK2DRD2DRD3 | |
| SCHEMBL2548897 | 0.88 | CCNT1 (0.37) | — | |
| SCHEMBL14616826 | 0.87 | RIPK2 (0.38) | KDM1ADRD2DRD3 | |
| SCHEMBL2553463 | 0.86 | MTOR (0.35) | — | |
| SCHEMBL2551527 | 0.86 | MTOR (0.35) | — | |
| SCHEMBL14576181 | 0.84 | TTK (0.30) | DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | claimed |
| EP-2552208-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | KDM1A 628/4885MAP3K11 19/4885WDR5 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.